LIVERMORE, Calif., Oct. 18 /PRNewswire/ -- Halt Medical, Inc. announced today that it has been approved to market the Tulip Radiofrequency Volumetric Thermal Ablation (RFVTA) probe in Canada. “The license we just received from Health Canada brings us an important step closer to our goal of making our uterine sparing procedure available to the millions of women in North America who suffer with uterine fibroids”, said Russ DeLonzor, President and COO of Halt Medical. “The approvals we’ve now received from Canada and the European Union for general use and for treating uterine fibroids, plus our recent clearance by the FDA to market our products for general surgical use (not specifically indicated for fibroids) in the United States has us well positioned to bring our solutions to most of the major global markets in the near future”, said DeLonzor.
About Halt Medical, Inc.
Halt Medical, Inc. is a medical device design and manufacturing company based near San Francisco, CA developing products to ablate tissue with its next generation RFVTA system. The Halt system has been cleared by the FDA for general use and is currently being studied in the US and Latin America for relief of symptoms caused by uterine fibroids. Halt is preparing to commercialize the Halt Fibroid System in markets outside the US where it has already been approved for general surgical and fibroid indications. The worldwide business opportunity for the Halt Fibroid System is estimated to be over $2billion annually.
Information about the Halt Fibroid Study and a list of clinical sites in the U.S. may be found at www.clinicaltrials.gov, study number NCT00874029.
SOURCE Halt Medical, Inc.
